H1B Salary Data

Home › Employers › Laurus Generics, Inc.

Laurus Generics, Inc.: H-1B salaries and sponsorship

Laurus Generics, Inc. filed 3 labor condition applications for H-1B and related visas in fiscal years 2023–2026; certified: 2. Median offered salary: $74,888.

Applications (LCAs)3
Certified2
Employer addressBerkely Heights, NJ
H-1B dependent employerNo
Median offered salary$74,888
Middle half of salaries$68,863–$80,914
10th–90th percentile$65,247–$84,530

Does Laurus Generics, Inc. sponsor H-1B visas?

Laurus Generics, Inc. filed 3 labor condition applications in fiscal years 2023–2026, the latest submitted on Apr 2, 2026. An LCA is the first step of an H-1B petition, so the employer has sponsored or prepared to sponsor H-1B workers; it does not guarantee sponsorship for any particular job. Check the employer's own job listings.

Salaries by job title

Job titleLCAsMedian salary
Quality Assurance and Pharmacovigilance Associate2$62,837
Assistant Manager, BD1$86,940

Applications by fiscal year

Fiscal yearLCAsMedian salary
FY20231$86,940
FY20262$62,837

Prevailing wage levels

The Department of Labor sets four prevailing wage levels for each occupation and area, from Level I (entry) to Level IV (fully competent). The employer picks the level that matches the job's requirements.

Where the jobs are

Occupations

Latest applications

Job titleBase salaryLocationSubmittedStart dateStatus
Quality Assurance and Pharmacovigilance Associate$62,837–$73,000
Level I
Berkeley Heights, NJApr 2, 2026Oct 1, 2026Certified
Quality Assurance and Pharmacovigilance Associate$62,837–$73,000
Level I
Berkeley Heights, NJApr 2, 2026Oct 1, 2026Withdrawn
Assistant Manager, BD$86,940
Level III
Grafton, MAApr 5, 2023Oct 1, 2023Certified

Salaries are the lower end of the wage offered on each application, converted to a yearly amount; statistics use certified full-time applications only. An LCA is not a visa approval and one LCA can cover several positions. Source: U.S. Department of Labor, OFLC LCA Disclosure Data, fiscal years 2023–2026 (latest decision Jun 30, 2026).